Overview
Observe long-term safety risk and long-term efficacy after intravenous infusion of BHC001 in TDT subjects.
Description
Observe long-term delayed safety risks such as emerging neoplasms, emerging haematological disorders, and long-term efficacy after intravenous infusion of BHC001 in TDT subjects.
Eligibility
Inclusion Criteria:
- Provision of written informed consent for this study by subjects, or as applicable, subject's parent(s)/legal guardian(s)
- Treated with BRL-101 for therapy of transfusion-dependent β-thalassemia.
Exclusion Criteria:
- There are no exclusion criteria for this study